725 reports of this reaction
4.8% of all EMICIZUMAB reports
#4 most reported adverse reaction
OFF LABEL USE is the #4 most commonly reported adverse reaction for EMICIZUMAB, manufactured by Genentech, Inc.. There are 725 FDA adverse event reports linking EMICIZUMAB to OFF LABEL USE. This represents approximately 4.8% of all 15,224 adverse event reports for this drug.
Patients taking EMICIZUMAB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among EMICIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for EMICIZUMAB:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 725 FDA reports for EMICIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 4.8% of all adverse event reports for EMICIZUMAB, making it a notable side effect.
If you experience off label use while taking EMICIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.